Apr 2 2014
The demand for Gilead Sciences' Sovaldi, which costs $1,000 a pill, indicates how hard it is for insurers to curb the use of life-saving medicines. Meanwhile Humana names a former Goldman Sachs executive as finance chief.
The Wall Street Journal: Sales Soar For Pricey Hepatitis Drug Sovaldi
A hepatitis C pill from Gilead Sciences Inc. that costs $1,000 a day is on track to notch among the biggest sales ever for the first year of a newly approved drug, showing just how hard it is for insurers to curb the use of pricey life-saving medicines (Rockoff, 3/31).
In other marketplace news -
The Wall Street Journal: Humana Names Brian Kane Finance Chief
Brian Kane, 41 years old, will join Humana after spending nearly 17 years at Goldman Sachs, where he was responsible for leading financing transactions for a number of companies across multiple industries. Mr. Kane's health- insurance work has included coverage of the national and government-focused managed care organizations (Kell, 3/31).
|
 This article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.
|
50 years of lifesaving vaccinations: WHO's EPI saves 154 million lives